Acepodia

Acepodia is a clinical-stage biotechnology company founded in 2017 by Dr. Patrick Y. Yang and Dr. Sonny Hsiao, headquartered in Alameda, California with operations in Taipei, Taiwan. It develops off-the-shelf allogeneic cell therapies for cancer and autoimmune disease built on two proprietary platforms: Antibody-Cell Conjugation (ACC), which uses bioorthogonal click chemistry from Carolyn Bertozzi's Nobel Prize-winning work to attach tumor-targeting antibodies to gamma delta 2 T cells and natural killer cells without genetic engineering, and Antibody-Dual-Drugs Conjugation (AD2C). Its clinical pipeline includes ACE1831, an anti-CD20 gamma delta T cell therapy, and ACE2016, an anti-EGFR gamma delta T cell therapy. Acepodia is a therapeutics developer rather than a software vendor, and publishes no public API, developer portal, or machine-readable specification.

Acepodia is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Cell Therapy, Oncology, and Immunotherapy.

Acepodia’s developer surface includes product news and 16 more developer resources.

🌐 Visit website 📡 Source on GitHub

11.1/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-17 · rubric v0.11.0

0 APIs

CompanyBiotechnologyCell TherapyOncologyImmunotherapyLife SciencesClinical StageHealthcare

Kin Score

Kin Score How this is scored →
scored 2026-08-17 · rubric v0.11.0

Composite quality — 11.1/100 · minimal

Contract Quality 0.0 / 21

Developer Ergonomics 0.0 / 17

Commercial Clarity 3.6 / 17

Operational Transparency 0.0 / 11

Governance 0.0 / 10

Discoverability 4.9 / 9

Regulatory Posture 2.6 / 15

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 10

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

A2A Agent Card 0 / 8

Dry-Run / Simulate Mode 0 / 4

Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.

The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/acepodia: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Agent Surfaces 2

MCP servers, agent skills, and machine-readable catalogs

WellKnown

WellKnown

LLMsTxt

LLMsTxt

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Operate 2

Status, limits, changes, and where to get help

Contact

Contact

PressReleases

PressReleases

Commercial 2

Pricing, plans, and the legal terms of use

PrivacyPolicy

PrivacyPolicy

TermsOfService

TermsOfService

Company 6

The organization behind the API

Website

About

Careers

Partnerships

News

LinkedIn

Other 4

Properties that don't map to a standard resource type

Leadership

Technology

Pipeline

SecondaryMarket

Source (apis.yml)

aid: acepodia
name: Acepodia
description: 'Acepodia is a clinical-stage biotechnology company founded in 2017 by Dr. Patrick Y. Yang and Dr. Sonny Hsiao,
  headquartered in Alameda, California with operations in Taipei, Taiwan. It develops off-the-shelf allogeneic cell therapies
  for cancer and autoimmune disease built on two proprietary platforms: Antibody-Cell Conjugation (ACC), which uses bioorthogonal
  click chemistry from Carolyn Bertozzi''s Nobel Prize-winning work to attach tumor-targeting antibodies to gamma delta 2
  T cells and natural killer cells without genetic engineering, and Antibody-Dual-Drugs Conjugation (AD2C). Its clinical pipeline
  includes ACE1831, an anti-CD20 gamma delta T cell therapy, and ACE2016, an anti-EGFR gamma delta T cell therapy. Acepodia
  is a therapeutics developer rather than a software vendor, and publishes no public API, developer portal, or machine-readable
  specification.'
image: https://www.acepodia.com/upload/base_fb_img/enL_01ns_web_base_20K06_uiwbgs3abs.png
url: https://raw.githubusercontent.com/api-evangelist/acepodia/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.20'
created: '2026-08-06'
modified: '2026-08-06'
tags:
- Company
- Biotechnology
- Cell Therapy
- Oncology
- Immunotherapy
- Life Sciences
- Clinical Stage
- Healthcare
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: Website
  url: https://www.acepodia.com/
- type: About
  url: https://www.acepodia.com/about/
- type: Contact
  url: https://www.acepodia.com/contact/
- type: Careers
  url: https://www.acepodia.com/careers/
- type: Leadership
  url: https://www.acepodia.com/leadership/
- type: Technology
  url: https://www.acepodia.com/technology/
- type: Pipeline
  url: https://www.acepodia.com/pipeline/
- type: Partnerships
  url: https://www.acepodia.com/partnerships/
- type: News
  url: https://www.acepodia.com/newsroom/
- type: PressReleases
  url: https://www.acepodia.com/newsroom/press-releases/
- type: PrivacyPolicy
  url: https://www.acepodia.com/legal/privacy/
- type: TermsOfService
  url: https://www.acepodia.com/legal/terms-of-use/
- type: LinkedIn
  url: https://www.linkedin.com/company/acepodia/
- type: DomainSecurity
  url: security/acepodia-domain-security.yml
- type: WellKnown
  url: well-known/acepodia-well-known.yml
- type: LLMsTxt
  url: llms/acepodia-llms.txt
- type: SecondaryMarket
  url: https://forgeglobal.com/acepodia_stock/
x-enrichment:
  date: '2026-08-06'
  status: minimal
  artifacts_added: 3
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: Acepodia is a clinical-stage cell-therapy developer whose published sitemap.xml lists 38 URLs, every one of them
    corporate (about, leadership, technology, pipeline, newsroom, partnerships, careers, legal) — no api., developer., docs.,
    portal., app., status. or trust. host resolves for acepodia.com, no acepodia GitHub organisation exists, and every /.well-known/
    and conventional spec path on www.acepodia.com returns the site's own HTML 404 page.
  evidence:
  - url: https://www.acepodia.com/sitemap.xml
    status: 200
  - url: https://www.acepodia.com/openapi.json
    status: 404
  - url: https://www.acepodia.com/.well-known/agent-card.json
    status: 404
  - url: https://www.acepodia.com/.well-known/security.txt
    status: 404
  - url: https://www.acepodia.com/llms.txt
    status: 404
  - url: https://api.github.com/orgs/acepodia
    status: 404
  checked: '2026-08-06'